Clearside Biomedical
CLSD
CLSD was delisted on the 28th of November, 2025.
42 hedge funds and large institutions have $39.1M invested in Clearside Biomedical in 2020 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 10 increasing their positions, 10 reducing their positions, and 7 closing their positions.
112% more capital invested
Capital invested by funds: $18.4M → $39.1M (+$20.6M)
14% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 7
2% more funds holding
Funds holding: 41 → 42 (+1)
0.24% more ownership
Funds ownership: 1.72% → 1.97% (+0.24%)
0% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CG
Carmignac Gestion
Paris,
France
|
+$1.9M |
| 2 |
ACP
Acuta Capital Partners
Redwood City,
California
|
+$1.1M |
| 3 |
Millennium Management
New York
|
+$118K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$83.1K |
| 5 |
SF
Synovus Financial
Columbus,
Georgia
|
+$48.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$120K |
| 2 |
S
SignatureFD
Atlanta,
Georgia
|
-$113K |
| 3 |
Two Sigma Investments
New York
|
-$106K |
| 4 |
Principal Financial Group
Des Moines,
Iowa
|
-$104K |
| 5 |
Two Sigma Advisers
New York
|
-$92.2K |
CLSD Hedge Fund Activity: Q4 2020 in Review
42 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Clearside Biomedical (CLSD) for Q4 2020, worth a combined $39.1M — up 112% from $18.4M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new CLSD positions and 7 closed out — a net gain of 1 holder — while 10 added to existing stakes and 10 trimmed.
The largest buyer was Carmignac Gestion, adding an estimated $1.9M. The largest seller was Renaissance Technologies, cutting an estimated $120K.
- 42 institutional investors held Clearside Biomedical (CLSD) as of Q4 2020, up from 41 in Q3 2020.
- Funds reported $39.1M of Clearside Biomedical stock for Q4 2020, up 112% quarter-over-quarter.
- 8 funds opened new Clearside Biomedical positions in Q4 2020 and 7 closed out, a net change of +1 holder.
- The largest Clearside Biomedical buyer in Q4 2020 was Carmignac Gestion, an estimated $1.9M added.
- The largest Clearside Biomedical seller in Q4 2020 was Renaissance Technologies, an estimated $120K sold.
Based on aggregated 13F filings for Q4 2020.